

Pierre-Jean Lamy

Group: Languedoc-Mutualité, Montpellier, France

E-mail: pierre-jean.lamy@labosud-ocbiologie.fr

General research subject: prognostic and predictive biomarkers in breast and prostate cancer

Available techniques: NGS, qPCR, Mass-spectrometry, Immunoanalysis,

Group website: http://www.languedoc-mutualite.fr/Recherche-clinique/L-unite-de-recherche-clinique-de-Languedoc-Mutualite_753_.html

Publications since 2013

P-J Lamy, P-M Martin, G Romieu, W Jacot. Re: Clinical Validity/Utility, Change in Practice Patterns, and Economic Implications of Risk Stratifiers to Predict Outcomes for Early-Stage Breast Cancer: A Systematic review. *J Natl Cancer Inst.* 2013 Jan 16;105(2):149

W. Jacot, M. Fiche, Khalil Z., A. Wolfer, **P.-J. Lamy**. The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond. *Biochim Biophys Acta.* 2013 Aug 1, 1836:146-57

F. Mouliere, C. Gongora, A. Guedj, B. Robert, S. EL Messaoudi, M. Del Rio, F. Molina, **P.-J. Lamy**, et al. Detection of high mutation load in circulating DNA from colorectal cancer patients with KRAS and BRAF point mutation enables the non-invasive molecular analysis of tumors. *Transl Oncol.* 2013 Jun 1;6(3):319-28

A. Durigova, **P.-J. Lamy**, S. Thezenas, S. Pouderoux, F. Montels, G. Romieu, M. Gutowski, W. Jacot. Anemia and iron deficiency in early breast cancer patients. Diagnostic value of hepcidin and soluble transferrin receptor. *Clin Chem Lab Med.* 2013 Jun 20:1-9. doi: 10.1515/cclm-2013-0031. [Epub ahead of print]

J. Jacquemier, F. Spyrtos, B. Esterni, M.-J. Mozziconacci, M. Antoine, L. Arnould, S. Lizard, P. Bertheau, J. Lehmann-Che, C. Blanc Fournier, S. Krieger, F. Bibeau, **P.J. Lamy**, et al. CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: A multicenter experience based on 840 cases. *BMC Cancer.* 2013 Jul 22;13(1):351

Maynadier M, Farnoud R, **Lamy PJ**, Laurent-Matha V, Garcia M, Rochefort H. Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment. *Int J Oncol.* 2013 Sep 10.

Firmin N, **Lamy PJ**, Romieu G, Jacot W. Vitamin D and breast cancer: Physiopathology, biological and clinical implications. *Bull Cancer.* 2013 Oct 8. [Epub ahead of print] PubMed PMID: 24103818.

Lamy PJ, Montels F, Tosi D, Leizour B, Bascoul-Mollevis C, Castan F, Roques S, Nielloud F, Rebillard X. Evaluation of (-2)proPSA in combination with total PSA and free PSA for the early detection of prostate cancer. *Ann Biol Clin (Paris).* 2013 Oct 1;71(5):537-544.

Emile JF, Tisserand J, Bergougnoux L, Nowak F, Faucher G, Surel S, Lamy A, *et al.* . Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. *BMC Cancer*. 2013 Oct 11;13:472. doi: 10.1186/1471-2407-13-472

Jacot W, Thezenas S, Senal R, Viglianti C, Laberrenne AC, Lopez-Crapez E, Bibeau F, Bleuse JP, Romieu G, **Lamy PJ**. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. *BMC Cancer*. 2013 Nov 5;13(1):523.

H. Saadoun, **P.-J. Lamy**, S. Thezenas, S. Pouderoux, F. Bibeau, F. Montels, G. Romieu, P.-E. Colombo, M. Gutowski, W. Jacot. Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision making for early breast cancer. *Futur Oncology* 2014; 10:195-209

P.-J. Lamy et W. Jacot. Place des biomarqueurs tissulaires dans la prise en charge du cancer du sein. *Journal de Biologie Médicale. J Bio Med*. 2014;2(8):266-8

Menegaux F, Anger A, Randrianasolo H, Mulot C, Laurent-Puig P, Iborra F, Bringer JP, Leizour B, Thuret R, **Lamy PJ**, Rébillard X, Trétarre B; EPICAP Study Group. Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France. *BMC Cancer*. 2014 Feb 19;14(1):106

P.-J. Lamy et A.-S. Gauchez Septième Symposium bioclinique « Biomarqueurs du cancer de la prostate : innovations et perspectives » *Médecine Nucléaire* 38 (2014) 2

P.-J. Lamy. The level of evidence for the use of PSA and other biomarkers in the early detection of prostate *Médecine Nucléaire* 38 (2014) 2

Y. Fulla , A.-S. Gauchez , F. Thuiller , J.-F. Morin, A. Charrie , C. Sault , **P.-J. Lamy** , X. Rebillard ? Réévaluation des dosages de PSA disponibles en France en 2012. *Médecine Nucléaire* 38 (2014) 2

Menegaux F, Anger A, Randrianasolo H, Mulot C, Laurent-Puig P, Iborra F, Bringer JP, Leizour B, Thuret R, **Lamy PJ**, Rébillard X, Trétarre B; EPICAP Study Group. Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France. *BMC Cancer*. 2014 Feb 19;14(1):106

Luporsi, E., Bellocq, J. P., Barrière, J., Bonastre, J., Chetritt, J., Le Corroller, A. G., de Cremoux, P., Fina, F., Gauchez, A. S., **Lamy, P. J.**, Martin, P. M., Mazouni, C., Peyrat, J. P., Romieu, G., Verdoni, L., Mazeau-Woynar, V., and Kassab-Chahmi, D. UPA/PAI-1, ONCOTYPE DXtm, MAMMAPRINT® - Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du sein. In: INCa (ed.), *Etat des lieux et des connaissances Pratique clinique*, 2014.

Thierry AR, Moulriere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, **Lamy PJ**, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. *Nat Med*. 2014 Mar 23. doi: 10.1038/nm.3511

P.-J. Lamy. The level of evidence for the use of PSA and other biomarkers in the early detection of prostate cancer (*Appropriatezza e predittività dei biomarcatori di carcinoma prostatico*) J of Ligand Assay 18 (4) 2013: 236-9

P.-J. Lamy, A. Durigova, W. Jacot. Iron homeostasis and anemia markers in early breast cancer. Clin Chim Acta. 2014 Apr 23. pii: S0009-8981(14)00167-3.

El Demery M, Demirdjian-Sarkissian G, Thezenas S, Jacot W, Laghzali Y, Darbouret B, Culine S, Rebillard X, **Lamy P-J:** Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer, Clinical and Translational Medicine 2014, 3:31

Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, Le Caer H, Moro-Sibilot D, Fournel P, Oster JP, Chatellain P, Barre P, Jeannin G, Mourlanette P, Derollez M, Herman D, Renault A, Dayen C, **Lamy PJ,** Langlais A, Morin F, Zalzman G; on behalf of the French Cooperative Thoracic Intergroup (IFCT); on behalf of the French Cooperative Thoracic Intergroup IFCT. Randomized Phase II-III Study of Bevacizumab in Combination with Chemotherapy in Previously Untreated Extensive Small-Cell Lung Cancer: Results from the IFCT-0802 Trial. Ann Oncol. 2015 Feb 16. pii: mdv065.

W Jacot, C Theillet, S Guiu, **P-J Lamy.** Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations? Futur Oncol 2015. Vol. 11, No. 4, Pages 557-559

Lamy PJ, Plassot C, Pujol JL. Serum HE4: An Independent Prognostic Factor in Non-Small Cell Lung Cancer. PLoS One. 2015 Jun 1;10(6):e0128836. doi:10.1371/journal.pone.0128836. eCollection 2015.

Lamy PJ, Castan F, Lozano N, Monté lion C, Audran P, Bibeau F, Roques S, Montels F, Laberrenne AC. Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies. J Mol Diagn. 2015 Jul;17(4):366-73.

Luporsi E, Bellocq JP, Barrière J, Bonastre J, Chetritt J, Le Corroller AG, de Cremoux P, Fina F, Gauchez AS, **Lamy PJ,** et al. [uPA/PAI-1, Oncotype DX?, MammaPrint®]. Prognosis and predictive values for clinical utility in breast cancer management]. Bull Cancer. 2015 Sep;102(9):719-29.

P-J Lamy. Quels biomarqueurs utiliser pour la détection précoce des cancers de la prostate? Ann Biol Clin (Paris). 2015 Nov 1;73(S1):29-30

Gauchez AS, **Lamy PJ,** Descotes JL. [The PSA caught out]. Prog Urol. 2015 Dec;25(16):1121-4.

W Jacot, C Mollevi, F Fina, E Lopez-Crapez, P-M Martin, P-E Colombo, F Bibeau, G Romieu and **P-J Lamy.** High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers. BMC Cancer Dec 2015, 15 :986

P.-J. Lamy, A.-S. Gauchez, L. Salomon, M. Haugh, J. Ceraline, Y. Fulla, A. Georges, S. Larré et al. Les niveaux de preuve des biomarqueurs utilisés pour la détection précoce des cancers de la prostate. *Ann Biol Clin (Paris)*.2016 Apr 1;74(2):227-232

W. Jacot, N. Firmin, L. Roca, D. Topart, S. Gallet, A. Durigova, S. Mirr, S. Pouderoux, V. D'Hondt, J.-P. Bleuse, **P.-J. Lamy**, G. Romieu. Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: the VitaCal randomized phase III study. *Ann Oncol*. 2016 Jul ;27(7) : 1253-41

Darlix A, **Lamy PJ**, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thezenas S, Jacot W. Serum HER2 extra-cellular domain, S100 β and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients. *BMC Cancer*.2016 Jul 7;16(1):428

P.-J. Lamy, C. Sault, E. Renard. High fasting serum insulin level due to autoantibody interference in insulin immunoassay discloses autoimmune insulin syndrome: a case report. *Ann Biol Clin (Paris)*. 2016 Aug 1;74(4):490-4

Darlix A, **Lamy PJ**, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thézenas S, Jacot W. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases? *Int J Cancer*. 2016 Jul 27

Antoinette Lemoine, Sébastien Couraud, Frédéric Fina, Sylvie Lantuejoul, **Pierre-Jean Lamy**, Marc Denis, Étienne Rouleau. Recommandations du GFCO pour l'utilisation diagnostique des analyses génétiques somatiques sur l'ADN tumoral circulant. *Innovation Therap Oncol* (2) 5, Sept-Oct 2016

Lefebvre T, Lasocki S, Fénéant-Thibault M, Lamy PJ, Cunat S, Ropert-Bouchet M, Aguilar-Martinez P, Lehmann S, Delaby C. Added value of hepcidin quantification for the diagnosis and follow-up of anemia-related diseases. *Ann Biol Clin (Paris)*. 2017 Feb 1;75(1):9-18

P-J Lamy; Y Allory; A-S Gauchez; B Asselain; P Beuzeboc; P De Cremoux; J Fontugne; A Georges; C Hennequin; J Lehmann-Che; C Massard; I Millet; T Murez; M-H Schlageter; O Rouvière; D Kassab-Chahmi; F Rozet; J- L Descotes; X Rebillard. Prognostic biomarkers used for localized prostate cancer management: a systematic review. *Eur Urol Focus* epub online.

A.-L. Giraudet, S. Bardet, M.-E. Toubert, **P.-J. Lamy**, S. Zerdoud, S. Leboulleux, J. Clerc, L. Leenhardt, C. Bournaud, A. Al Ghuzlan, I. Keller, L. Groussin, F. Sebag, R. Garrel, E. Miralliéo, D. Taïeb, E. Hindié. Molecular imaging and serum biomarkers in differentiated thyroid cancer: 2017 guidelines of the french Societies of nuclear medicine, endocrinology, pathology, biology, endocrine surgery and head and neck surgery. *Medecine Nucléaire* 2017 epub online

Slimane Zerdoud, Anne-Laure Giraudet, Sophie Leboulleux, Laurence Leenhardt, Stéphane Bardet, Jérôme Clerc, Marie-Elisabeth Toubert, Abir Al Ghuzlan, **Pierre-Jean Lamy**, Claire Bournaud, Isabelle Keller, Frédéric Sebag, Renaud Garrel, Eric Mirallié, Lionel Groussin, Elif Hindié, ?, David Taïeb. Consensus

Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery. Ann Endocrinol 2017.

M Viala, M Alexandre, S Thezenas, **P-J Lamy**, A Maran-Gonzales, M Gutowski, P-E Colombo, G Romieu, W Jacot, S Guiu. Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers. Breast Cancer Res and Treatment. 2017.

Solene Doat, Sylvie Cénée, Brigitte Trétarre, Xavier Rebillard, **Pierre-Jean Lamy**, Jean-Pierre Bringer, François Iborra, Thibaud Murez, Marie Sanchez, Florence Menegaux Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study. Cancer Science 2017 epub head online.

Akiko Chiba, Rachna Ramann, Alexandra Thomas, Simon Thezenas, Marie Viala, Stéphane Pouderoux, **Pierre-Jean Lamy**, Sarah L. Mott, Mary C. Schroeder, William Jacot. Serum Vitamin D Levels Impacts Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Clinical Breast Cancer. Submitted.

Shi, Liu; Géhin, Thomas; Chevolut, Yann; Souteyrand, Eliane; Jacot, William; **Lamy, Pierre-Jean**; Laurenceau, Emmanuelle. Quantification of uPA in breast tumor tissue extracts by microarray immunoassay: comparison with ELISA technology". Submitted